This is a retrospective analysis of 95 patients with myelofibrosis who were allografted
between 2001 and 2014. The aims of the study were to assess whether the outcome of …

Allogeneic hematopoietic stem cell transplant remains the only curative treatment for
myelofibrosis. Most post-transplantation events occur during the first two years and hence …

Myelofibrosis (MF) is a chronic progressive hematologic malignancy with a median overall
survival (OS) of approximately 6 years. Allogeneic hematopoietic stem cell transplantation …

Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several
small series have reported long-term disease-free survival (DSF) after allogeneic …

The choice of alternative donor is a major issue in allogeneic hematopoietic stem cell
transplantation (HSCT) for patients with primary myelofibrosis (PMF) without an HLA …

This analysis included 56 myelofibrosis (MF) patients transplanted from family mismatched
donor between 2009 and 2015 enrolled in the European Society for Blood and Marrow …

Myelofibrosis, either de novo or following pre-existing hematologic diseases, can be cured
by allogeneic hematopoietic stem cell transplantation (SCT), but SCT is associated with …

Modifications of transplant-conditioning regimens have reduced transplant-related mortality
and allow carrying out successful HCT in increasingly older patients. The selection of …

We aimed to evaluate the determinants of survival in myelofibrosis patients undergoing
allogeneic hematopoietic cell transplantation (allo-HCT) and to describe factors predicting …

Allogeneic haematopoietic stem‐cell transplantation (HSCT) is the only curative treatment
for myelofibrosis. We report an analysis of the Société Française de Greffe de Moelle et de …